Alkeus Pharmaceuticals, Inc.
Alkeus Pharmaceuticals, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for rare and serious diseases. Founded in 2011, Alkeus has made significant strides in the field of ophthalmology, particularly in addressing unmet medical needs associated with inherited retinal diseases. The company’s flagship product, a novel treatment for Stargardt disease, exemplifies its commitment to advancing patient care through unique therapeutic approaches. Alkeus is recognised for its robust pipeline and dedication to research, positioning itself as a leader in the rare disease sector. With a strong emphasis on scientific excellence and patient-centric solutions, Alkeus Pharmaceuticals continues to make impactful contributions to the biopharmaceutical landscape.
DitchCarbon Score
How does Alkeus Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alkeus Pharmaceuticals, Inc.'s score of 18 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alkeus Pharmaceuticals, Inc.'s reported carbon emissions
Alkeus Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the absence of data does not preclude the company from engaging in climate initiatives or setting future sustainability goals. As the pharmaceutical industry increasingly prioritises environmental responsibility, Alkeus may consider aligning with industry standards and frameworks to enhance its climate strategy.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alkeus Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
